PMID- 33888105
OWN - NLM
STAT- MEDLINE
DCOM- 20211206
LR  - 20211214
IS  - 2662-7671 (Electronic)
IS  - 2662-7671 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Apr 22
TI  - The beneficial effects of the composite probiotics from camel milk on glucose and 
      lipid metabolism, liver and renal function and gut microbiota in db/db mice.
PG  - 127
LID - 10.1186/s12906-021-03303-4 [doi]
LID - 127
AB  - BACKGROUND: Probiotics may have beneficial effects on patients with type 2 
      diabetes mellitus (T2DM). We separated 4 lactobacillus and 1 saccharomycetes from 
      traditional fermented cheese whey (TFCW) and prepared composite probiotics from 
      camel milk (CPCM) and investigated their effects on glucose and lipid metabolism, 
      liver and renal function and gut microbiota in db/db mice. METHODS: CPCM was 
      prepared in the laboratory and 40 db/db mice were randomly divided into 4 groups 
      as metformin, low-dose and high-dose group and model group, and treated for 
      6 weeks. In addition, 10 C57BL/Ks mice as normal control group were used for 
      comparison. Fasting blood glucose (FBG), body weight (BW), oral glucose tolerance 
      test (OGTT), glycated hemoglobin (HbAlc), C-peptide (CP), triglycerides (TG), 
      total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high density 
      lipoprotein cholesterol (HDL-C), 24 h urinary microalbumin (24 h malb), urine 
      ketone, urine sugar, pancreas and liver tissue and intestinal flora were tested. 
      RESULTS: Compared to diabetic group, high dose CPCM significantly decreased FBG, 
      OGTT, HbAlc and IRI, plasma TC, TG, LDL-C, 24 h malb, urine ketone and urine 
      sugar, increased CP, HDL-C levels, improved the liver and kidney function, 
      protected the function of islets, also increased intestinal tract lactic acid 
      bacteria and Bifidobacterium, decreased Escherichia in db/db mice. CONCLUSION: 
      CPCM decreased FBG, OGTT and HbAlc, increased CP, modulated lipid metabolism and 
      improved liver and kidney protected injury in db/db mice, which may be related to 
      various probiotics acting through protecting the function of islets and 
      regulating intestinal flora disturbance.
FAU - Manaer, Tabusi
AU  - Manaer T
AD  - College of Pharmaceutical Sciences, Xinjiang Medical University, Urumqi, 830011, 
      China.
AD  - Xinjiang Uygur Autonomous Region Institute for Drug Control, Urumqi, 830054, 
      China.
FAU - Yu, Lan
AU  - Yu L
AD  - College of Pharmaceutical Sciences, Xinjiang Medical University, Urumqi, 830011, 
      China.
AD  - The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830011, 
      China.
FAU - Nabi, Xin-Hua
AU  - Nabi XH
AUID- ORCID: 0000-0001-9191-6839
AD  - College of Pharmaceutical Sciences, Xinjiang Medical University, Urumqi, 830011, 
      China. xinhuanabi@126.com.
FAU - Dilidaxi, Dinareer
AU  - Dilidaxi D
AD  - College of Pharmaceutical Sciences, Xinjiang Medical University, Urumqi, 830011, 
      China.
FAU - Liu, Lu
AU  - Liu L
AD  - College of Pharmaceutical Sciences, Xinjiang Medical University, Urumqi, 830011, 
      China.
FAU - Sailike, Jialehasibieke
AU  - Sailike J
AD  - College of Pharmaceutical Sciences, Xinjiang Medical University, Urumqi, 830011, 
      China.
LA  - eng
GR  - 81160344/National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20210422
PL  - England
TA  - BMC Complement Med Ther
JT  - BMC complementary medicine and therapies
JID - 101761232
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - *Camelus
MH  - *Diabetes Mellitus, Type 2
MH  - Female
MH  - Gastrointestinal Microbiome/*drug effects
MH  - Glucose/metabolism
MH  - Lipid Metabolism/drug effects
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Milk/microbiology
MH  - Phytotherapy
MH  - Probiotics/*pharmacology
MH  - Random Allocation
PMC - PMC8061000
OTO - NOTNLM
OT  - Composite probiotics camel milk
OT  - Gut microbiota
OT  - TFCW
OT  - TG
OT  - db/db mice
COIS- The authors declare that they have no competing interests.
EDAT- 2021/04/24 06:00
MHDA- 2021/12/15 06:00
PMCR- 2021/04/22
CRDT- 2021/04/23 05:31
PHST- 2020/07/04 00:00 [received]
PHST- 2021/04/13 00:00 [accepted]
PHST- 2021/04/23 05:31 [entrez]
PHST- 2021/04/24 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/04/22 00:00 [pmc-release]
AID - 10.1186/s12906-021-03303-4 [pii]
AID - 3303 [pii]
AID - 10.1186/s12906-021-03303-4 [doi]
PST - epublish
SO  - BMC Complement Med Ther. 2021 Apr 22;21(1):127. doi: 10.1186/s12906-021-03303-4.